Company: BGLC
Filing Date: 2025-12-03
Form Type: DEF 14A
Source: 0001477932-25-008757
Chunk: 11

Company: BioNexus Gene Lab Corp
Filing Date: 2025-12-03
Form: DEF 14A
Chunk 11
---
 The four nominees are the four current members of our Board of Directors.

Directors typically are elected for a period of one year and thereafter serve until the next annual meeting at which the nominee is reelected or a successor is duly elected by our stockholders, or until his or her successor is duly elected and qualified. Each nominee for election has agreed to serve if elected, and we have no reason to believe that any nominee will be unavailable to serve.

Nominees

The following table sets forth the name, age and positions of each of our director nominees as of the date of this Proxy Statement. Each of the nominees listed below is currently a director of the Company and has been elected to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified.

| Name                           |     | Age |     | Position                                                                                                                                       |
| Su-Leng Tan Lee                |     |  42 |     | Chief Executive Officer, President, and Director                                                                                               |
| Jook Yuen Low                  |     |  48 |     | Director, Member of Audit and Nominating Committees                                                                                            |
| Muhammad Azrul bin Abdul Hamid |     |  50 |     | Director, Member of the Audit Committee, Chairman of the Compensation Committee, Chairman of the Corporate Governance and Nominating Committee |
| Chee Keong Yap                 |     |  70 |     | Director, Chairman of the Audit Committee, Member of the Compensation Committee                                                                |

Business Experience and Directorships

The following describes the background of our directors.

Su-Leng Tan Lee has been a Director of the Company since December 2023, and has over 20 years of extensive experience in a variety of industries, including information systems, hospitality, investment management, construction, property development, travel, government liaison, and life sciences, primarily focused on commercialization, finance, and general management. Since August 2023, Mr. Tan has served as the Company’s Chief Operating Officer, and then as Company’s Chief Executive Officer. Since May 2022, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. Since August 2017, Mr. Tan worked as the FLO Life Sciences Group’s owner and Managing Director, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From July 2018 to April 2019, Mr